A Phase 3 interventional study of linezolid and vancomycin in Febrile Neutropenia, sponsored by Pfizer. Completed at 40 sites in 10 countries. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2009-12-01.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Febrile Neutropenia with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Febrile Neutropenia · United States.
Among the 18 studies in Febrile Neutropenia with a site in United States, this one is the 7th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2001, is one of 3 in phase 3, and was the 1st registered.
147 studies on the registry are indexed under Febrile Neutropenia; 36 are open to participants now.
Browse Febrile Neutropenia studies →1 of the 18 studies in Febrile Neutropenia with a site in United States is open now. Recruiting first, the newest first:
IDION Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Febrile Neutropenia studies recruiting now, 11 (58%) set no upper age limit and 8 (42%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.
This study: 13 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 3 · Phase 4 1
First in 2001; this study’s year is marked. 1 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is close to the median of 120 across 95 interventional studies indexed under Febrile Neutropenia.
Median enrollment 131 across the 12 interventional studies, 162 across the 6 observational. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 18 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 4 studies filed under Febrile Neutropenia — fewer than ten, so there is no comparison to draw.
1 of the studies in Febrile Neutropenia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03078010Memorial Sloan Kettering Cancer CenterChoosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Febrile Neutropenia with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will treat patients who have fever and neutropenia (after cancer chemotherapy) that is possibly due to a specific bacteria (gram positive bacteria).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have neutropenia (ANC less than 500) with fever (oral temp 38.3 C).
Patients must have a cancer with recent chemotherapy and risks factors for gram positive infections.
Exclusion Criteria:
Patients with fever due to known causes. Patients with . Patients with recent bone marrow transplant. Patients with an infected indwelling catheter that cannot be removed. Patients who have received more than one day of another antibiotic before entering the trial.
Patients with endocarditis, osteomyelitis, meningitis, CNS infections.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be stratified according to the use of prophylactic antibiotics. Both groups may receive open-label gram-negative coverage with either ceftazidime, aztreonam, and/or aminoglycosides (gentamicin, tobramycin, amikacin). Subjects will receive study medication intravenously every 12 hours for 7 to 28 days.
Drug: linezolid
Drug: vancomycin
600mg every 12 hours
Also known as: Zyvox
1gm every 12 hours. The dose of vancomycin intravenously may be adjusted for renal function, but the patient must be able to receive a 300 mL volume of intravenous fluid at the assigned dosing times of every 12 hours.
Clinical efficacy of linezolid when administered intravenously as compared to intravenously administered vancomycin in the empiric treatment of oncology patients with febrile neutropenia with suspected gram-positive infections.
Time frame: 7-28 days
Microbiologic outcome
Time frame: 7-28 days
Pathogen eradication (eradication rates of individual pathogens)
Time frame: 7-28 days
Defervescence (defined as Tmax orally or rectally)
Time frame: 7-28 days
Time to defervescence
Time frame: 7-28 days
Resolution of neutropenia (return of ANC to >500 cells/mm3)
Time frame: 7-28 days
Time to resolution of neutropenia
Time frame: 7-28 days
Mortality rate (survival at 7 days after the end of therapy)
Time frame: 7-28 days
The record gives a start of Nov 2001 and a completion of Nov 2002. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Linezolid · Vancomycin